Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.82 |
| ▸ | KDR | P35968 | 15/20 | 0.82 |
| ▸ | FGFR1 | P11362 | 13/20 | 0.82 |
| ▸ | FLT1 | P17948 | 13/20 | 0.82 |
| ▸ | FLT4 | P35916 | 13/20 | 0.82 |
| ▸ | RET | P07949 | 3/20 | 0.82 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.82 |
| ▸ | TEK | Q02763 | 2/20 | 0.82 |
| ▸ | SRC | P12931 | 2/20 | 0.82 |
| ▸ | KIF5B | P33176 | 2/20 | 0.82 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.82 |
| ▸ | PLK4 | O00444 | 1/20 | 0.82 |
| ▸ | CIT | O14578 | 1/20 | 0.82 |
| ▸ | GAK | O14976 | 1/20 | 0.82 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.82 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.82 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.82 |
| ▸ | STK10 | O94804 | 1/20 | 0.82 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.82 |
| ▸ | ABL1 | P00519 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12534441 | 0.91 | EGFR (0.85) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL29352879 | 0.90 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL9044 | 0.90 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL2136770 | 0.90 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL28224661 | 0.90 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL2137353 | 0.90 | EGFR (0.98) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL4637084 | 0.90 | EGFR (0.98) | EGFRKDRFGFR1FLT1FLT4 | |
| Vandetanib SCHEMBL1614458 | 0.90 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 | |
| SCHEMBL21473656 | 0.89 | EGFR (0.81) | EGFRKDRFGFR1FLT1FLT4 | |
| Hydrochloric Acid SCHEMBL2140851 | 0.89 | EGFR (1.00) | EGFRKDRFGFR1FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| WO-2008108741-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*BIO PTE LTD (SG) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | EGFR 310/4885KDR 2584/4885FGFR1 2026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.